Erste Group Bank Brokers Decrease Earnings Estimates for NVO

Key Points

• Erste Group Bank lowered its FY2026 EPS estimate for Novo Nordisk to $3.20 from $3.22, below the broader consensus estimate of $3.39.
• Novo Nordisk reported quarterly revenue of $10.85 billion and EPS of $1.03, with a 37.23% net margin and 63.31% return on equity.
• Analyst sentiment remains cautious: five analysts rate the stock Buy, 15 Hold, and two Sell, producing an overall “Hold” rating and a consensus price target of $65.56.

Novo Nordisk A/S (NYSE:NVO - Free Report) - Stock analysts at Erste Group Bank cut their FY2026 earnings estimates for shares of Novo Nordisk A/S in a research note issued to investors on Monday, July 27th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.20 per share for the year, down from their previous estimate of $3.22. The consensus estimate for Novo Nordisk A/S's current full-year earnings is $3.39 per share.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion during the quarter.

NVO has been the topic of a number of other research reports. Nordea Equity Research raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Friday, June 19th. Citigroup reissued a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. Zacks Research lowered Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Monday, July 13th. Finally, HSBC reiterated a "hold" rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $65.56.

Novo Nordisk A/S Trading Down 0.1%

NYSE NVO opened at $51.55 on Friday. The stock has a market capitalization of $230.17 billion, a P/E ratio of 12.10, a P/E/G ratio of 4.70 and a beta of 0.77. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The firm has a 50-day moving average price of $46.87 and a 200 day moving average price of $45.49. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently modified their holdings of NVO. Godfrey Financial Associates Inc. acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $25,000. Scarborough Advisors LLC acquired a new position in Novo Nordisk A/S during the first quarter worth $26,000. WealthCollab LLC boosted its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after purchasing an additional 260 shares in the last quarter. American National Bank & Trust purchased a new stake in Novo Nordisk A/S during the fourth quarter worth $28,000. Finally, Maseco LLP acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $29,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Expanded Wegovy access: Novo Nordisk partnered with Crux to offer simpler benefit designs and more predictable pricing for U.S. employer health plans. The agreement could reduce affordability barriers and broaden access to Wegovy, supporting future prescription growth. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Positive Sentiment: Oral Wegovy opportunity: The European Commission’s approval of Novo’s once-daily oral Wegovy pill provides a new growth avenue in obesity treatment. Combined with the U.S. employer-access deal, the developments have encouraged optimism about wider GLP-1 adoption. Novo Nordisk Is Up After EU Wegovy Pill Approval And US Access Deal
• Positive Sentiment: Strong underlying product demand: Analysts expect Ozempic and Wegovy sales to be the primary focus of the upcoming second-quarter report, with oral launches and label expansions potentially supporting continued growth. Broader investor commentary also identifies Novo as a major beneficiary of the expanding GLP-1 market. How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?
• Neutral Sentiment: Results approaching: Investors are waiting for quarterly evidence that Ozempic and Wegovy sales can offset mounting competitive pressure. The earnings report may be a near-term catalyst, but expectations could also increase volatility if sales, pricing, or guidance disappoint. How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?
• Negative Sentiment: CagriSema litigation: A U.S. judge allowed parts of a shareholder lawsuit to proceed. Investors allege Novo misled them about a key CagriSema clinical trial, creating legal, reputational, and potential financial risks for the company’s next-generation obesity pipeline. Why Shareholders Are Suing Novo Nordisk Over CagriSema
• Negative Sentiment: Valuation and competition concerns: Commentary argues that much of Novo’s GLP-1 opportunity may already be reflected in the stock, while competitive pressure could limit upside and pricing power. Novo Nordisk: Too Late For A Great Opportunity

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.